ArticleMultiple sclerosis journal - experimental, translational and clinical

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Robert T Naismith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.